

Haematologica
HAEMATOL/2018/203968
Version 2

Infections and vaccination in hereditary hemorrhagic telangiectasia:
microbiological evidence-based considerations

Hanny Al-Samkari, Athena Kritharis, and David J Kuter

Disclosures: Al-Samkari: Consultancy (AgiOS). Kritharis: There are no relationships to disclose. Kuter: Research funding (Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios, Syntimmune, Principia, Alnylam); Consultancy (ONO, Pfizer, 3SBios, Eisai, GlaxoSmithKline, Genzyme, Shire, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Bioverativ, Argenx, Zafgen); Paid expert testimony (Amgen, CRICO).

Contributions: H. Al-Samkari collected data, analyzed data, created the table, and wrote and revised the manuscript; A. Kritharis revised the manuscript; D. Kuter critically revised the manuscript.